References
- Ahmadi S, Powell FC. Pyoderma gangrenosum: uncommon presentations. Clin Dermatol. 2005;23:612–620.
- Perry HO, Brunsting LA. Pyoderma gangrenosum; a clinical study of nineteen cases. AMA Arch Derm. 1957;75:380–386.
- Brooklyn T, Dunnill G, Probert C, et al. Diagnosis and treatment of pyoderma gangrenosum. BMJ. 2006;333:181–184.
- Bister V, Mäkitalo L, Jeskanen L, et al. Expression of MMP-9, MMP-10 and TNF-alpha and lack of epithelial MMP-1 and MMP-26 characterize pyoderma gangrenosum. J Cutan Pathol. 2007;34:889–898.
- Marzano AV, et al. Autoinflammatory skin disorders in inflammatory bowel diseases, pyoderma gangrenosum and Sweet’s syndrome: a comprehensive review and disease classification criteria. Clin Rev Allergy Immunol. 2013;45:202–210.
- Sandborn WJ, Tremaine WJ, Batts KP, et al. Pouchitis after ileal pouch-anal anastomosis: a Pouchitis Disease Activity Index. Mayo Clin Proc. 1994;69:409–415.
- Ampuero J, Rojas-Feria M, Castro-Fernández M, et al. Predictive factors for erythema nodosum and pyoderma gangrenosum in inflammatory bowel disease. J Gastroenterol Hepatol. 2014;29:291–295.
- Subramani K, Harpaz N, Bilotta J, et al. Refractory pouchitis: does it reflect underlying Crohn’s disease? Gut. 1993;34:1539–1542.
- Abdelrazeq AS, Lund JN, Leveson SH, et al. Pouchitis-associated pyoderma gangrenosum following restorative proctocolectomy for ulcerative colitis. Eur J Gastroenterol Hepatol. 2004;16:1057–1058.
- Yanaru-Fujisawa R, Matsumoto T, Nakamura S, et al. Granulocyte apheresis for pouchitis with arthritis and pyoderma gangrenosum after restorative proctocolectomy for ulcerative colitis: a case report. Inflamm Bowel Dis. 2005;11:780–781.
- Molnar T, Farkas K, Nagy F, et al. Successful use of infliximab for treating fistulizing pouchitis with severe extraintestinal manifestation: a case report. Inflamm Bowel Dis. 2008;14:1752–1753.
- Baumgart DC, Wiedenmann B, Dignass AU, et al. Successful therapy of refractory pyoderma gangrenosum and periorbital phlegmona with tacrolimus (FK506) in ulcerative colitis. Inflamm Bowel Dis. 2004;10:421–424.
- Arivarasan K, Bhardwaj V, Sud S, et al. Biologics for the treatment of pyoderma gangrenosum in ulcerative colitis. Intest Res. 2016;14:365–368.
- Jolles S, Niclasse S, Benson E, et al. Combination oral and topical tacrolimus in therapy-resistant pyoderma gangrenosum. Br J Dermatol. 1999;140:564–551.
- Mancini GJ, Floyd L, Solla JA, et al. Parastomal pyoderma gangrenosum: a case report and literature review. Am Surg. 2002;68:824–826.
- Brooklyn TN, Williams AM, Dunnill MGS, et al. T-cell receptor repertoire in pyoderma gangrenosum: evidence for clonal expansions and trafficking. Br J Dermatol. 2007;157:960–966.
- Sigal NH, Dumont FJ. Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. Annu Rev Immunol. 1992;10:519–560.
- Minami N, Yoshino T, Matsuura M, et al. Tacrolimus or infliximab for severe ulcerative colitis: short-term and long-term data from a retrospective observational study. BMJ Open Gastroenterol. 2015;2:e000021.